The FINANCIAL — Daiichi Sankyo Company, Limited on December 1 announced its decision to close its research subsidiary, U3 Pharma GmbH.
Daiichi Sankyo intends to strengthen its global research and development capabilities by increasing efficiency and streamlining processes. Based on this objective, the global R&D capacities have been reviewed and the Company has decided to concentrate core research functions of Daiichi Sankyo Group in future.
U3, with about 40 employees and which is engaged in research and development work on antibody targeting for cancer treatments, will transfer its current research and development tasks to the Biologics Function in Tokyo, according to Daiichi Sankyo.
Daiichi Sankyo will provide a more detailed update on the impact of this announcement on its FY2015 business results at a later date.
Discussion about this post